Soligenix completes $7.5 million public offering with warrants

Soligenix Inc. (NASDAQ: SNGX) announced the completion of its public offering, raising approximately $7.5 million in gross proceeds before fees and expenses.

The Princeton, New Jersey-based biopharmaceutical company sold 5,555,560 shares of common stock and accompanying warrants at a combined price of $1.35 per share. The warrants carry an exercise price of $1.35 per share, are immediately exercisable, and expire five years from issuance.

The company also amended existing warrants from May 2023, April 2024, and July 2024 offerings, covering 1,162,064 shares, reducing their exercise price to $1.35 per share to match the new warrants' terms.

According to the company's statement, the funding extends its cash runway through the end of 2026. Soligenix plans to use the net proceeds for research and development, commercialization activities, working capital, and general corporate purposes.

A.G.P./Alliance Global Partners served as the sole placement agent for the offering. The securities were offered under a registration statement on Form S-1 filed with the Securities and Exchange Commission on September 19, 2025, which became effective on September 25, 2025.

Soligenix focuses on developing treatments for rare diseases with unmet medical needs. The company operates two business segments: Specialized BioTherapeutics, which includes its HyBryte photodynamic therapy for cutaneous T-cell lymphoma, and Public Health Solutions, encompassing vaccine programs for ricin toxin, filoviruses, and COVID-19.

You May Also Be Interested In

• AEVEX prices public offering of 8 million shares at $27 each
• Jade Biosciences announces underwritten public offering of common stock
• Jianzhi Education completes $5 million registered direct offering